Video-assisted thoracic surgery (VATS) evaluation of intrathoracic disease in patients with FIGO III and IV stage ovarian cancer

Ovarian Cancer: Sites of Recurrence

“…10 Some patients with pleural effusions underwent thoracoscopy. 11 Chemotherapy was with paclitaxel (175 mg/m 2 ) and carboplatin (AUC 5) given intravenously at least 6 times, at 21-day intervals. The evaluation performed at chemotherapy included a clinical examination; a serum CA125 assay; and CT of the chest, the abdomen, and the pelvis.…”

The impact of pleural disease on the management of advanced ovarian cancer

“…VATS has been demonstrated in several studies [4,5,17,18,27,28] to be a useful technique for describing the extent of pleural disease, allowing to take biopsies when macroscopic lesions are found, treating symptomatic effusions and above all, selecting patients for upfront debulking surgery or neoadjuvant chemotherapy.…”

“…Among them, 31% avoided a potentially morbid abdominal cytoreductive surgery that would have left of N1 cm of intrathoracic disease behind. In another study, Klar et al [27] included 17 patients with suspected supra-diaphragmatic involvement at chest CT. VATS altered the therapeutic management in 6 patients leading to an upstaging compared to the CT results of 3 patients and to a down-staging of 3 other. In their study, VATS showed negligible morbidity related to surgery and short operating time, improving the accuracy of FIGO staging.…”

Role of Video-Assisted Thoracoscopy in Advanced Ovarian Cancer: A Literature Review

“…Video-assisted thoracoscopic surgery led to a change in disease stage or management in 76 patients (41%). Among the 82 patients with pleural effusions, 9,12,14,16 VATS revealed pleural disease in 47 patients (57%). Of the 64 patients in whom pleural aspiration was performed for cytologic examination, 47 (73%) had positive pleural cytology.…”

“…Klar et al 16 published a case series designed to assess the influence of VATS on treatment decisions in patients with stage III and IV ovarian cancer. Eligibility criteria for this study included suspected supradiaphragmatic involvement (pleural effusions, pleural carcinomatosis, lung metastasis, or enlarged supradiaphragmatic lymph nodes) on chest CT.…”